ReviewTherapeutic advances in vaccines and immunotherapy2021
Strategies for active and passive pediatric RSV immunization.
Review in Therapeutic advances in vaccines and immunotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 31 citations in OpenAlex.
- Phase 1/2a Safety and Immunogenicity of an Adenovirus 26 Vector Respiratory Syncytial Virus (RSV) Vaccine Encoding Prefusion F in Adults 18-50 Years and RSV-Seropositive Children 12-24 Months.The Journal of infectious diseases · 2022Trial
- Live-attenuated vaccines of human respiratory syncytial virus for infants and young children: Progress and prospects of an old yet promising platform.Biosafety and health · 2026Review
- Taxonomy of the Full Health and Societal Value of Maternal Vaccination to Prevent Infant Respiratory Syncytial Virus Disease.Infectious diseases and therapy · 2026Review
- Maternal RSV immunization: clinical efficacy, immunological mechanisms and public health implications for preventing infant lower respiratory tract infection.Journal of health, population, and nutrition · 2026Review
- Analysis of the Specific Expression Profile of Immune Cells in Infants and Young Children Infected with RSV and Construction of a Disease Prediction Model.Tropical medicine and infectious disease · 2025Article
- Review
- Respiratory Viral Detection in Children Hospitalized With Pneumonia During Periods of Major Population Disruptions in Nepal, 2014-2018.Journal of the Pediatric Infectious Diseases Society · 2025Article
- Expert consensus on the burden of respiratory syncytial virus disease and the utility of nirsevimab for disease prevention and protection of infants.World journal of pediatrics : WJP · 2025Review
- Preventing RSV Infection in Children: Current Passive Immunizations and Vaccine Development.Pathogens (Basel, Switzerland) · 2025Review
- A self-amplifying RNA RSV prefusion-F vaccine elicits potent immunity in pre-exposed and naïve non-human primates.Nature communications · 2024Article
- Antibody-mediated protection against respiratory syncytial virus in children.European respiratory review : an official journal of the European Respiratory Society · 2024Review
- A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12-24 Months.Open forum infectious diseases · 2024Article
- Epidemiology of Bronchiolitis and Respiratory Syncytial Virus and Analysis of Length of Stay from 2015 to 2022: Retrospective Observational Study of Hospital Discharge Records from an Italian Southern Province before and during the COVID-19 Pandemic.Diseases (Basel, Switzerland) · 2024Article
- From setbacks to success: lessons from the journey of RSV vaccine development.Therapeutic advances in vaccines and immunotherapy · 2024Review
- Exacerbated lung inflammation in offspring with high maternal antibody levels following secondary RSV exposure.Frontiers in immunology · 2024Article
- Respiratory Syncytial Virus Vaccines: A Review of the Candidates and the Approved Vaccines.Pathogens (Basel, Switzerland) · 2023Review
- Article
- Article
- Protecting the Offspring, the Gift of Maternal Immunization: Current Status and Future Perspectives.Vaccines · 2022Review
- Characterisation of RSV Fusion Proteins from South African Patients with RSV Disease, 2019 to 2020.Viruses · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infections in children worldwide, with the most severe disease occurring in very young infants. Despite half a century of research there still are no licensed RSV vaccines. Difficulties in RSV vaccine development stem from a number of factors, including: (a) a very short time frame between birth and first RSV exposure; (b) interfering effects of maternal antibodies; and (c) differentially regulated immune responses in infants causing a marked T helper 2 (Th2) immune bias. This review seeks to provide an age-specific understanding of RSV immunity critical to the development of a successful pediatric RSV vaccine. Historical and future approaches to the prevention of infant RSV are reviewed, including passive protection using monoclonal antibodies or maternal immunization strategies versus active infant immunization using pre-fusion forms of RSV F protein antigens formulated with novel adjuvants such as Advax that avoid excess Th2 immune polarization.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.